Cytokinetics doses first subject in Phase I CK-274 trial

7th December 2018 (Last Updated December 7th, 2018 00:00)

Cytokinetics has dosed the first subject in a Phase I trial evaluating the safety and tolerability of CK-3773274 (CK-274) to treat hypertrophic cardiomyopathy (HCM).

Cytokinetics doses first subject in Phase I CK-274 trial
Hypertrophic cardiomyopathy is the most common inherited cardiovascular disorder. Credit: Patrick J. Lynch, medical illustrator.

Cytokinetics has dosed the first subject in a Phase I trial evaluating the safety and tolerability of CK-3773274 (CK-274) to treat hypertrophic cardiomyopathy (HCM).

HCM is the most common inherited cardiovascular disorder that is estimated to affect around one in 500 individuals globally.

Cytokinetics aims to assess single and multiple oral doses of CK-274 in healthy subjects as part of the double-blind, randomised, placebo-controlled trial.

The multi-part trial comprises eight single and three multiple ascending dose cohorts consisting of eight subjects each.

Key endpoints include explaining the pharmacokinetics (PK) of CK-274 and its pharmacodynamic effects (PD) as measured by echocardiography.

"This first trial will elaborate on CK-274 and its potential to be best-in-class and we look forward to reporting data in 2019."

It will also characterise the relationship between the PK and PD of CK-274 for cardiac function.

Cytokinetics Research and Development executive vice-president of Fady Malik said: “The start of clinical trials for CK-274 marks an important milestone in our continuing innovation of potential sarcomere-directed medicines.

“Our scientists pioneered this emerging area of muscle pharmacology and have now advanced a next-generation drug candidate that was optimized for pharmacokinetic properties and therapeutic index.

“This first trial will elaborate on CK-274 and its potential to be best-in-class and we look forward to reporting data in 2019.”

CK-274 is a new, oral, small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with HCM.

The drug has previously been able to minimise myocardial contractility by binding directly to cardiac myosin at a separate and selective allosteric binding site.